Intravacc one of the “5 Most Trusted Vaccine Manufacturing Companies in 2023
>READ MORE
In vitro alternative assay to the replace rabbit pyrogen test for vaccines.
In vitro alternative assay to the replace rabbit pyrogen test for vaccines. Intravacc, in close collaboration with MAT services at Sanquin Diagnostic Services, announced the publication of a scientific article of an in vitro alternative assay to the replace rabbit pyrogen test for vaccines. Vaccines are essential for public health, but safety is paramount. The…
Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention
Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention Intravacc’s recent research, featured in the peer-reviewed journal ‘Current Opinion in Immunology’ Volume 84 (2023), explores the potential of OMV-based vaccines in mucosal immunization. OMVs, derived from Gram-negative bacteria, demonstrate promise as versatile vaccine candidates. Administered intranasally, they exhibit the capacity to carry diverse…
Enabling Tech Transfer of B. pertussis OMV Technology to our Partner Chonquing Zhifei Biological Products
Enabling Tech Transfer of B. pertussis OMV Technology to our Partner Chonquing Zhifei Biological Products In June, we successfully facilitated a Tech Transfer of “B. pertussis Outer Membrane Vesicle technology” to our colleagues from Zhifei at our laboratories in Bilthoven. This tech transfer is a testament to the strong relationship we built over the years…
Intravacc publishes 2022 annual report
Intravacc publishes 2022 annual report Bilthoven, the Netherlands, 29 June 2023 – Intravacc B.V., a leading CDMO for infectious diseases and therapeutic vaccines, announced today the publication of its 2022 annual report and the appointment of Frieda Gerdes, PhD as Vice President Business Development and Marketing. On May 3rd the Dutch State announced the sale…
Looking back on a successful Bio International 2023 in Boston!
Intravacc recently participated in the renowned “Bio International Conference” held in Boston.
Meet the new Business Development Team
Meet Intravacc’s new Business Development Team. A team of experienced professionals, dedicated to the success of your project.
Dutch State Announces the Sale of Intravacc B.V. (The Netherlands)
Dutch State Announces the Sale of Intravacc B.V. (The Netherlands) The Hague, The Netherlands, 3 May 2023 – The State of the Netherlands, the Dutch Ministry of Health, Welfare and Sport today announces its intentions to sell 100% of the issued and outstanding shares in the capital of Intravacc B.V. through a controlled auction process.…
Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow
Intravacc’s CSO Virgil Schijns appointed as Visiting Professor at the Scottish University of Strathclyde in Glasgow Appointment for three years at the Strathclyde Institute of Pharmacy and Biomedical Sciences Schijns published over 120 scientific papers in the field of immunology and adjuvants Bilthoven, The Netherlands, 23 February 2023 – Intravacc, a world leader in…
